ReviewOncology reviews2023
Multimodal Management of Colorectal Liver Metastases: State of the Art.
Review in Oncology reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Review
- Upfront Thermal Ablation versus Neoadjuvant Chemotherapy Followed by Ablation for Oligometastatic Colorectal Liver Metastases: A Propensity Score Matching Analysis.Cardiovascular and interventional radiology · 2026Article
- Colorectal Liver Metastases in the Post-COLLISION Era: Choosing the Right Local Tool, not the Winning Modality.Annals of surgical oncology · 2026Article
- Treatment Patterns and Prognostic Nomograms for Overall Survival and Hepatic Progression-Free Survival in Unresectable Colorectal Liver Metastases Treated with Drug-Eluting Bead Chemoembolization: A Single-Center Study.Current oncology (Toronto, Ont.) · 2026Article
- Multimodal prediction of metachronous liver metastasis in stage I-III colorectal cancer patients: multicenter cohort study employing machine learning.Abdominal radiology (New York) · 2026Article
- FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy.BMC cancer · 2026Article
- Immunotherapy-Based Conversion to Curative-Intent Treatment in Hepatocellular Carcinoma: A Multidisciplinary Framework.Cancers · 2026Review
- The State of the Art on Management of Patients with Unresectable Liver Metastases from Colorectal Cancer.Biomedicines · 2026Review
- Deciphering Colorectal Liver Metastasis Perfusion Heterogeneity: Identification of Distinct Vascular Phenotypes through High-Lateral-Resolution Photoacoustic Microscopy.Radiology. Imaging cancer · 2026Article
- Beyond the image: achieving complete pathologic response in MSI-high metastatic colon cancer despite persistent PET activity.International journal of surgery case reports · 2026Article
- Cancer metastasisFrontiers in bioengineering and biotechnology · 2026Review
- Efficacy and safety of percutaneous microwave ablation for liver tumors using an antenna with anti-phase technology offering ultraspherical ablation.Radiology and oncology · 2025Article
- A machine learning-based prediction model for colorectal liver metastasis.Clinical and experimental medicine · 2025Article
- Surgical Resection Versus Microwave Ablation for Colorectal Liver Oligometastases: A Multicenter Cohort Study of 1027 Patients.Journal of gastrointestinal cancer · 2025Article
- Therapeutic Potentials of MiRNA for Colorectal Cancer Liver Metastasis Treatment: A Narrative Review.Iranian journal of medical sciences · 2025Review
- Implementation of Hepatic Artery Infusion Pump Therapy: Real-World Single-Center Experience.Journal of surgical oncology · 2025Article
- Comparison of CT-Guided Microwave Ablation of Liver Malignancies with and Without Intra-Arterial Catheter Placement for Contrast Administration.Current oncology (Toronto, Ont.) · 2025Article
- Patterns and Predictors of Recurrence After Curative Resection of Colorectal Liver Metastasis (CRLM).Journal of gastrointestinal cancer · 2024Article
- Risk Factors for Death from Heart Disease in Elderly Colon Cancer Patients with Liver Metastasis.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver is the most common site of colorectal cancer (CRC) metastases. Treatment of CRC liver metastases (CRLM) includes different strategies, prevalently based on the clinical and oncological intent. Valid approaches in liver-limited or liver-prevalent disease include surgery, percutaneous ablative procedures (radiofrequency ablation, microwave ablation), intra-arterial perfusional techniques (chemo-embolization, radio-embolization) as well as stereotactic radiotherapy. Systemic treatments, including chemotherapy, immunotherapy and other biological agents, are the only options for patients with no chance of locoregional approaches. The use of chemotherapy in other settings, such as neoadjuvant, adjuvant or conversion therapy of CRLM, is commonly accepted in the clinical practice, although data from several clinical trials have been mostly inconclusive. The optimal integration of all these strategies, when applicable and clinically indicated, should be ever considered in patients affected by CRLM based on clinical evidence and multidisciplinary experience. Here we revised in detail all the possible therapeutic approaches of CRLM focusing on the current evidences, the studies still in progress and the often contradictory data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.